Abstract
Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) is globally increasing and has become a world-wide health problem. Chronic infection with hepatitis B virus or hepatitis C virus (HCV) is associated with hepatic steatosis. Viral hepatitis-associated hepatic steatosis is often caused by metabolic syndrome including obesity, type 2 diabetes mellitus and/or dyslipidemia. It has been reported that HCV genotype 3 exerts direct metabolic effects that lead to hepatic steatosis. In this review, the differences between NAFLD/NASH and viral hepatitis-associated steatosis are discussed.
Keywords:
Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis.
MeSH terms
-
Animals
-
Antiviral Agents / therapeutic use
-
Biomarkers / blood
-
Fatty Liver / diagnosis
-
Fatty Liver / drug therapy
-
Fatty Liver / epidemiology*
-
Fatty Liver / virology
-
Hepatitis B, Chronic / diagnosis
-
Hepatitis B, Chronic / drug therapy
-
Hepatitis B, Chronic / epidemiology*
-
Hepatitis B, Chronic / virology
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy
-
Hepatitis C, Chronic / epidemiology*
-
Hepatitis C, Chronic / virology
-
Humans
-
Liver Cirrhosis / diagnosis
-
Liver Cirrhosis / drug therapy
-
Liver Cirrhosis / epidemiology*
-
Liver Cirrhosis / virology
-
Non-alcoholic Fatty Liver Disease / diagnosis
-
Non-alcoholic Fatty Liver Disease / epidemiology*
-
Predictive Value of Tests
-
Prevalence
-
Prognosis
-
Risk Factors
Substances
-
Antiviral Agents
-
Biomarkers